

Role of plasma Progastrin phenotypes as a potential biomarker for screening and diagnosis of cancer - A Scoping Review

ABSTRACT

INTRODUCTION: Globally, over 18 million new cancer cases are identified and approximately 10 million people have died from this disease in 2018. Over the years, biomarkers have developed with several applications in the field of cancer research; one such biomarker is progastrin - a neuropeptide hormone, a precursor of gastrin hormone and secreted by the G cells of the antrum. Among the various phenotypes produced, Hpg80 and ProGastrin peptide realizing hormone (Pro GRP) are the two most common types seen among patients with cancer.

AIM: The aim of this scoping review is to gather literature on the role of Hpg80 and Pro GRP in common type of carcinomas occurring globally which include Lung, gastric, breasts, head neck and oral cancer.

MATERIALS AND METHODS: Relevant studies were searched via MEDLINE (PUBMED), COCHRANE and GOOGLE SCHOLAR and 9 relevant studies were reviewed based on the inclusion and exclusion criteria from the period of January 2012 to December 2021.

RESULTS: The main findings point to provide concrete evidence associating elevated levels of Hpg80 and Pro GRP in Lung carcinoma.

CONCLUSION: In light of the increasing interest in cancer diagnosis, Hpg80 and Pro GRP can be considered as a differentiating marker in screening and diagnosis of carcinomas.

Keywords: Biomarker, Human Progastrin 80, carcinoma, screening

1. INTRODUCTION

In 2015, cancer was the second leading cause of non -communicable disease deaths in the world. Globally, over 18 million new cancer cases were identified and approximately 10 million people died from the disease in 2018.^[1] The projected incidence of patients with cancer in India among males was 679,421 (94.1 per 100,000) and among females 712,758 (103.6 per 100,000) for the year 2020. One in 68 males (lung cancer), 1 in 29 females (breast cancer), and 1 in 9 Indians will develop cancer during their lifetime.^[2] Contributing factors such as tobacco smoking, urbanization, pollution, diet and a rapidly aging population have been theorized to be responsible for this explosive cancer incidence.^[3] Representations of cancer have always been a mystery since most cancer remains asymptomatic. Even if there are any symptoms present, they are nonspecific like lymphadenopathy, weight loss, or persistent cough. Thus, these are ignored by the patients due to their poor literacy skills, financial or cultural barriers.^[4]

By the time the patients seek a medical care, the care becomes economically costlier or availability of care is difficult. Moreover, late detection of cancer makes treatment difficult because of progressive advancement in disease stage and metastasis. Although early detection programs have increased, particularly in the developed world, such programs typically rely on symptomatic presentation. However, early cancer symptoms can be nonspecific and can be easily confused for other conditions, contributing to the delay in diagnosis and the progression of the disease.^[5]

Over the years biopsy has been the gold standard in detecting and confirming cancer conditions, but one up roaring field of cancer diagnostics is search of novel biomarkers. Biomarker is a molecule that can be detected in blood, saliva or any body fluid indicating a pathological condition.^[6] Over the years, biomarkers have developed several applications in the field of cancer research that they are not only restricted to diagnosis but also used to evaluate risk assessment, differential diagnosis, determination of prognosis, prediction of treatment and monitor progression of cancer.^[7] Literature is abundant on the importance of various cytogenic and circulating biomarkers and their role in various cancers, including lung, colon etc.

28 One such biomarker of interest is progastrin - a neuropeptide hormone, a precursor of gastrin hormone and is found to
29 mature to various phenotypes upon enzyme reactions. Progastrin is a polypeptide and is encoded by the GAST gene
30 (GeneID: 14459). Among the various phenotypes produced Human Progastrin 80 (Hpg80) and ProGastrin peptide
31 realizing hormone (Pro GRP) are the two most common types seen among patients with cancer.^[8] Various theories have
32 been proposed to understand how a pro hormone behaves as a biomarker for cancer. One acceptable hypothesis is
33 proGRP act as growth modifying factor which induces cell proliferation and maturation along with pro angiogenesis.^[9]
34 Even though progastrin is physiological hormone having important functions, its pathological role in cancers can further be
35 attributed with the fact that the gene GAST coding for progastrin is a direct target gene of the WNT/ β -catenin oncogenic
36 pathway. The activation of this oncogenic pathway is an early event in cancer development. Chronic activation of the
37 WNT/ β -catenin oncogenic pathway occurs in almost all human solid tumors and is a central mechanism in cancer biology
38 that induces cellular proliferation, blocking of differentiation leading to primary tumor growth and metastasis formation.^[10]
39 With this background, this scoping review was intended to gather literature on the role of Hpg80 and Pro GRP as a
40 potential biomarker for various cancers. The outcome of this research would throw light on the role of these biomarkers on
41 various cancer and thus could be suggested as an universal biomarker for general screening for cancer on a population
42 level program.

43 2. MATERIAL AND METHODS

44 2.1 DESIGN

45 This review was undertaken according to the criteria of Preferred Reporting Items for Systematic Reviews and Meta-
46 Analyses extension for Scoping Reviews (PRISMA-ScR)

51 2.2 REVIEW QUESTION

52 Role of Hpg80 and Pro GRP as potential biomarkers for various cancers.

54 2.3 INCLUSION CRITERIA

- 55 ✓ Studies which assessed Hpg80 and Pro GRP levels for cancer diagnosis, prognosis or treatment
- 56 monitoring
- 57 ✓ The search included only studies published in English.
- 58 ✓ Studies published in the last 10 years (2012 to 2021) were included.
- 59 ✓ Both Descriptive and analytical study designs were included

60 EXCLUSION CRITERIA

- 61 ✓ Qualitative studies, reviews, expert opinion, systematic reviews and meta-analysis
- 62 ✓ Publications with no abstract and those which were widely out of scope of the study were eliminated.
- 63 ✓ Studies that required translation to English language.

64 The remaining studies were sorted on basis of their title and abstract. Finally, those studies in which the abstract fulfill all
65 inclusion criteria were selected for full-text reading. In those cases, in which a study met the eligibility criteria but the
66 information in the abstract was insufficient, full texts of the articles were also obtained. Further literature search was
67 performed based on the bibliography of the selected articles.

68 2.4 SEARCH STRATEGY

69 Relevant studies were included from the period of January 2012 to December 2021 via MEDLINE (PUBMED),
70 COCHRANE and GOOGLE SCHOLAR. A detailed search strategy was developed for MEDLINE through the use of
71 MeSH terms and was modified for other search engines. 'Progastrin'; 'biomarker'; Cancer diagnosis (HEAD AND NECK);

BREAST; GASTRIC; COLORECTAL; OESOPHAGUS; LUNG; ORAL CANCER);' tumor';' early detection' were terms used along with Boolean operators "AND; 'OR'Data searches were done at September 2021 and again at January 2022. Manual searches were carried out with the reference list and also with journals that have a core scope on novel technologies used of cancer diagnosis. Although systematic reviews, qualitative studies, case series were excluded, reference lists were checked to ensure all primary research was located for inclusion. Only full papers written in English were included. Where multiple publications reporting on the same study existed in different databases, data from the study were extracted and reviewed only once. Duplication of article was identified using software. (Mendeley version 2.67)

2.5 STUDY SELECTION


Study selection was conducted by all authors (kappa value -0.8, computed using SPSS version 20) who independently screened titles and abstracts against the inclusion/ exclusion criteria and identified relevant papers. Then the authors independently reviewed the full text studies which fulfilled the inclusion and exclusion criteria. Comparison of papers was completed between the authors with no disagreements.

STUDY DESCRIPTION

Initial search yielded 40 studies for Lung Cancer, 60 studies for colorectal/gastric/esophageal cancer and 13 studies for head and neck cancer. There were null results for the "oral cancer" or "Breast cancer".

Among the final 9 studies, 8 studies represented lung cancer and one study on medullary thyroid carcinoma. All the studies evaluated progastrin phenotype ProGRP in serum using enzyme sorbent assay. (Figure 1)

Figure 1 shows the flow chart of articles narrowed down for final analysis.



A total of 121 studies were obtained initially which were evaluated for duplication and 9 relevant studies were selected based on the inclusion and exclusion criteria.

3. RESULTS

The outcome of the assessed studies have been described in Table 1.

LUNG CARCINOMA FINDINGS

Lung carcinoma being the most common type of cancer had 8 final studies, SCLC (small cell lung carcinoma) and NSCLC (non-small cell carcinoma) were conditions seen. Progastrin was considered to be one among the other biomarkers like CEA, SCC –An, CYFRA whose sensitivity and specificity ranged from 18%-76% and 57% to 97% respectively. ProGRP marker is an accurate biomarker to differentiate SCLC and NSCLC and it is also a reliable marker to diagnose SCLC. Levels of ProGRP is above <120ng/ml in case of malignant conditions and >>80ng/ml in benign cases.

HEAD AND NECK FINDINGS

Among the 9 studies only one study satisfied the eligibility criteria for analysis. In that study medullary thyroid carcinoma was the condition seen, the serum ProGRp measured had a sensitivity of 53% and specificity of 96.8% and it was concluded that progastrin was better at differentiating medullary thyroid carcinoma.

OTHER FINDINGS

No studies was done so far in the field of oral cancer and breast cancer diagnosis.

110
111
112

Table 1 shows the data extraction of the 9 studies included for final analysis.

Sl no.	Author, year	Disease studies	Method of progastrin analyzed	Result	Conclusion
1.	Barchiesi ^[11] V, 2021	Small cell lung cancer and Non small cell lung cancer differentiation	Serum proGRP	Increased levels of serum proGRP was seen among SCLC	proGRP is a accurate indicator for discrimating SCLC and non SCLC
2	Molina R ^[12] 2009	SCLC AND NSCLC	Serum proGRP	Increased levels seen among SCLC with sensitivity of 76.7% and specificity of 97.2%	ProGRP Can Be Used A Good Tumor Differentiation
3	Ni J ^[13] 2016	Clinical stages of lung carcinoma	ProGRP, SCC-Ag, Cyfra21-1 and CEA- serum levels	Increased levels seen with different stages with sensitivity and specificity of proGRP was 75.3% and 57.4%.	Serum proGRP predicts extensive stages
4	Korkamz ^[14] , 2018	Patients diagnosed with LC	Progastrin releasing peptide (ProGRP), squamous cell carcinoma antigen (SCCAg), cytokeratin 19-fragments (CYFRA 21.1), human epididymis protein 4 (HE4), Chromogranin A (CgA) and neuron specific enolase (NSE) levels were measured	sensitivity and specificity of tumormarkers were 72%, 83% for CYFRA 21.1; 70%, 57% for HE4; 18%, 93% for ProGRP; 43%, 77% for SCCAg; 54%, 53% for CgA; 73%, 50% for NSE	panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC
5	Molina R ^[15] 2004	Lung cancer	Serum pro GRP levels were measured	Abnormal lvels>80ng/ml was seen in benign conditions and >120ng/ml seen in malignancy.	proGRp is a more sensitive marker for SCLC
6	Uchida K ^[16] 2002	Patients with SCLC	Serum proGRP	proGRP protein expression was higher among SCLC	GRP may function as an autocrine growth factor for cancer cells in a subgroup of SCLC patients
7	Muley T ^[17] 2020	Patients with small-cell lung cancer (any stage) receiving chemotherapy	ProGRP was measured at baseline and after each chemotherapy	Decline(>.25%) in proGRP after cycle 1 and 2 showed zero intermittent progression of tumor in CT scan even after 2 weeks.	ProGRP may be a simple, reliable, and repeatable tool for monitoring response to chemotherapy and provide valuable

					prognostic information
8	Molina R ^[18] 2005	Marhker comparison among SCLC	ProGRP, CEA, SCC, CYFRA 21-1 and NSE	most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%)	ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type.
9	Liang 2020 ^[19]	Medullary thyroid carcinoma	Serum ProGRP and FNA-ProGRP were measured	serum ProGRP was increased with a 53.85% sensitivity, 96.98% specificity	ProGRP measurement could be served as an ancillary method for the differential diagnosis between MTC and non-MTC thyroid nodules

113 ProGRP – Progastrin Releasing Peptide, SCLC - Small Cell Lung Carcinoma, NSCLC -Non-Small Cell Lung Carcinoma,
114 LC – Lung Carcinoma, CYFRA - cytokeratin fragments, HE4 – Human Epididymis protein 4, NSE - Neuron Specific
115 Enolase, CgA - Chromogranin A, MTC – Medullary Thyroid Carcinoma, SCCAg - Squamous Cell Carcinoma Antigen,CEA
116 – Carcinoembryonic Antigen, CT – Computerized Tomography
117

118 4. DISCUSSION

119
120 Findings from the above scoping review provide concrete evidence on Lung carcinoma but not much exploration is done
121 in field of other carcinomas. The relationship between progastrin and cancer diagnosis is explained with the WNT –m
122 oncogenic pathways.

123 The WNT signalling pathway is an ancient and evolutionarily conserved pathway that regulates crucial aspects of cell fate
124 determination, cell migration, cell polarity, neural patterning and organogenesis during embryonic development. The
125 WNTs are secreted glycoproteins and comprise a large family of nineteen proteins in humans hinting to a daunting
126 complexity of signalling regulation, function and biological output.^[21]

127 A connection of the Wnt pathway to cancer was implicated by the discovery that activation of int1 (Wnt1), which, either by
128 proviral insertion into the Wnt1 locus or transgenic overexpression in mice, resulted in mammary hyperplasia and tumors.
129 Many experimental data further suggested that direct link between Wntsignalling and human cancer.^[22]

130 In the past years, many genetic and biochemical studies have sought to identify novel Wnt pathway components and their
131 functions. Identified components and processes include the Wnt secretory machinery, Wnt co-receptors, components of
132 the β -catenin destruction complex and nuclear co-factors. With the advance in sequencing technology and the
133 comprehensive structural characterization of cancer genomes it became evident that mutations in the Wnt pathway occur
134 frequently in human cancers.^[23] Progastrin (progrp) a physiological hormone is found in the blood of patients with different
135 cancers mostly lung and gastric. This could be explained by the theory that a gene GAST which codes directly for
136 progastrin is a target gene of WNT / β -catenin oncogenic pathway.^[24]

137 The activation of this oncogenic pathway is an early event in cancer development.

138 Chronic activation of the WNT/ β -catenin oncogenic pathway occurs in almost all human solid tumours and is a central
139 mechanism in cancer biology that induces cellular proliferation, blocking of differentiation leading to primary tumour
140 growth and metastasis formation.^[25]

141 Thus, Progastrin measured in the peripheral blood of patients on treatments, could be a new powerful marker for
142 diagnosis and prognosis at different stages. Thus, this scoping review is an attempt to understand the relation between
143 ProGRP levels and different carcinomas.

145 5. CONCLUSION

146
147 It can be concluded with the above findings that progastrin is definitely a reliable differentiating marker in lung carcinomas
148 and a good prognostic marker in head and neck cancers. To further understand the role of progastrin in oral cancer and
149 other different carcinomas more exploratory trials need to be conducted to cope up with the dearth of evidence present.
150

151 152 CONSENT (WHEREEVER APPLICABLE)

153
154 Since this was a literature review, consent was not applicable for this manuscript.
155
156

157 158 ETHICAL APPROVAL (WHEREEVER APPLICABLE)

159 Since this was a literature review, ethical approval was not applicable for this manuscript.
160

161 162 ACKNOWLEDGEMENT:

163 The authors would like to acknowledge the financial support received from the University Research Committee, The Tamil
164 Nadu Dr MGR Medical University for assessing the role of progastrin in malignancies.
165
166

167 168 REFERENCES

- 169 1. You B, Kepenekian V, Prieur A, Caceres M, Payen-Gay LF, Liaud P, et al. Progastrin, a new blood biomarker for
170 the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project. *Annals of*
171 *oncology*. 2018 ;29(8):37.
- 172 2. Oh H, Park HY, Kim KH, Park CK, Shin HJ, Lim JH, et al. Progastrin-releasing peptide as a diagnostic and
173 therapeutic biomarker of small cell lung cancer. *J Thorac Dis*. 2016;8(8):2530-37.
- 174 3. Dupuy M, Iltache S, Rivi re B, Prieur A, Pageaux GP, Bedoya JU, et al. Plasma hPG80 (Circulating Progastrin)
175 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma. *Cancers* 2022;14(2):402
- 176 4. Cappellini M, Flaceliere M, Saywell V, Soule J, Blanc E, Belouin F, et al. A novel method to detect hPG80 (human
177 circulating progastrin) in the blood. *Anal Methods*. 2021;13:4468-71.
- 178 5. Koepfel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, et al. Whole exome sequencing for
179 determination of tumor mutation load in liquid biopsy from advanced cancer patients. *PLoS One*. 2017;12(11):
180 e0188174.
- 181 6. Latini G, De Felice C, Barducci A, Dipaola L, Gentile M, Andreassi MG, et al. Clinical biomarkers for cancer
182 recognition and prevention: a novel approach with optical measurements. *Cancer Biomark*. 2018;22(2):179-198.
- 183 7. Henry LN and Hayes DF. Cancer biomarkers. *Mol oncol*. 2012;6(2):140-146.
- 184 8. Smith AM, Watson SA . Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma
185 sequence. *Gut* 2000;47(6): 820–24
- 186 9. Najib B, Chauvel AK, Do C, Roche S, Moyal CJ, Seva C. Progastrin a new pro angiogenic factor in colorectal
187 cancer. *Oncogene*. 2015;34(24):3120-30.
- 188 10. Siddheshwar RK, Gray JC, Kelly SB. Plasma levels of progastrin but not amidated gastrin or glycine extended
189 gastrin are elevated in patients with colorectal carcinoma. *Gut* 2001; 48(1): 47–52.
- 190 11. Barchiesi V, Simeon V, Sandomenico C, Cantile M, Cerasuolo D, Chiodini P, et al. Circulating progastrin-
191 releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring. *J*
192 *CircBiomark*. 2021 Jul 7; 10:9-13
- 193 12. Molina R, Aug  JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumor markers,
194 including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. *Tumour Biol*.
195 2009;30(3):121-9.
- 196 13. Ni J, Guo Z, Zhang L. The diagnostic significance of single or combination lung cancer-related serum biomarkers
197 in high risk lung cancer patients. *ZhonghuaNeiKe Za Zhi*. 2016 ;55(1):25-30.
- 198 14. Korkmaz ET, Koksal D, Aksu F, Dikmen ZG, Icne D, Maden E, et al. Triple test with tumor markers CYFRA 21.1,
199 HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. *ClinBiochem*. 2018 ;58:15-19.
- 200 15. Molina R, Filella X, Aug  JM. ProGRP: a new biomarker for small cell lung cancer. *Clin Biochem*. 2004
201 ;37(7):505-11.

- 202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
16. Uchida K, Kojima A, Morokawa N, Tanabe O, Anzai C, Kawakami M, et al. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. *J Cancer Res Clin Oncol.* 2002 ;128(12):633-40.
 17. Muley T, Zhang X, Holdenrieder S, Korse CM, Zhi XY, Molina R, et al. A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. *Tumour Biol.* 2020 ;42(9):1010428320958603..
 18. Molina R, Auge JM, Filella X, Vinolas N, Alicarta J, Domingo JM, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. *Anticancer Res.* 2005;25(3A):1773-8.
 19. Liang X, Zhu J, Cai M, Dai Z, Fang L, Chen H, et al..ProGRP as a novel biomarker for the differential diagnosis of medullary thyroid carcinoma in patients with thyroid nodules. *EndocrPract.* 2020 May;26(5):514-22.
 20. Farin HF, Jordens I, Mosa MH, Basak O, Korving J, Tauriello DVF et al. Visualization of a short-range Wnt gradient in the intestinal stem-cell niche. *Nature* 2016; 530(7590):340–43.
 21. Luga V, Zhang L, Vilorio-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. *Cell* 2012; 151(7):1542–56.
 22. Coudreuse DYM, Roël G, Betist MC, Destrée O, Korswagen HC. Wnt gradient formation requires retromer function in Wnt-producing cells. *Science* 2006; 312(5775): 921–924.
 23. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. *Proc Natl Acad Sci USA* 2012;109(29): 11717–11722.
 24. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med* 2013; 19(2):179–192.
 25. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. New insights into the mechanism of Wnt signaling pathway activation. *Int Rev Cell Mol Biol* 2011; 291: 21–71.

226
227